1. Home
  2. LEGN vs MIDD Comparison

LEGN vs MIDD Comparison

Compare LEGN & MIDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • MIDD
  • Stock Information
  • Founded
  • LEGN 2014
  • MIDD 1888
  • Country
  • LEGN United States
  • MIDD United States
  • Employees
  • LEGN N/A
  • MIDD N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • MIDD Industrial Machinery/Components
  • Sector
  • LEGN Health Care
  • MIDD Industrials
  • Exchange
  • LEGN Nasdaq
  • MIDD Nasdaq
  • Market Cap
  • LEGN 7.0B
  • MIDD 8.3B
  • IPO Year
  • LEGN 2020
  • MIDD N/A
  • Fundamental
  • Price
  • LEGN $33.65
  • MIDD $150.40
  • Analyst Decision
  • LEGN Strong Buy
  • MIDD Buy
  • Analyst Count
  • LEGN 13
  • MIDD 8
  • Target Price
  • LEGN $79.17
  • MIDD $180.29
  • AVG Volume (30 Days)
  • LEGN 1.1M
  • MIDD 719.5K
  • Earning Date
  • LEGN 03-11-2025
  • MIDD 05-07-2025
  • Dividend Yield
  • LEGN N/A
  • MIDD N/A
  • EPS Growth
  • LEGN N/A
  • MIDD 6.61
  • EPS
  • LEGN N/A
  • MIDD 7.90
  • Revenue
  • LEGN $627,241,000.00
  • MIDD $3,875,162,000.00
  • Revenue This Year
  • LEGN $66.60
  • MIDD $5.72
  • Revenue Next Year
  • LEGN $49.28
  • MIDD $3.98
  • P/E Ratio
  • LEGN N/A
  • MIDD $19.34
  • Revenue Growth
  • LEGN 119.97
  • MIDD N/A
  • 52 Week Low
  • LEGN $30.17
  • MIDD $118.41
  • 52 Week High
  • LEGN $60.87
  • MIDD $182.73
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 44.07
  • MIDD 41.94
  • Support Level
  • LEGN $34.00
  • MIDD $154.77
  • Resistance Level
  • LEGN $36.20
  • MIDD $159.28
  • Average True Range (ATR)
  • LEGN 1.52
  • MIDD 4.33
  • MACD
  • LEGN -0.25
  • MIDD 0.10
  • Stochastic Oscillator
  • LEGN 25.18
  • MIDD 44.65

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About MIDD Middleby Corporation (The)

The Middleby Corp is engaged in designing, manufacturing, marketing, distribution and service of a broad line of foodservice equipment used in all types of commercial restaurants and institutional kitchens, food preparation, cooking, baking, chilling and packaging equipment for food processing operations, and premium kitchen equipment including ranges, ovens, refrigerators, ventilation, dishwashers and outdoor cooking equipment used in the residential market. The company conducts its business through three principal business segments namely the Commercial Foodservice Equipment Group, the Food Processing Equipment Group and the Residential Kitchen Equipment Group. The firm derives majority revenue from Commercial Foodservice Equipment Group segment.

Share on Social Networks: